The Impact of Severe Exacerbations on Quality of Life and the Clinical Course of Chronic Obstructive Pulmonary Disease
Section snippets
Clinical effects of exacerbations
COPD exacerbations have serious clinical consequences. The reduction in lung function and associated symptoms seen at the onset of an exacerbation cause deterioration in patient quality of life (QOL) and a need for healthcare interventions, such as unscheduled medical visits and hospitalizations. Repeated exacerbations may accelerate the underlying severity of the disease by causing a more rapid rate of decline in lung function over time.
An increase in dyspnea is the most common symptom of
Exacerbations and progression of the underlying disease
There is some evidence to suggest that frequent exacerbations may accelerate the rate of decline of lung function over time in patients with COPD. Investigators in the Lung Health Study inferred exacerbation rates from the number of recorded physician visits for lower respiratory illnesses.16 Patients who continued to smoke had a more rapid decline in FEV1 than did patients who quit. Furthermore, among patients who continued to smoke, the decline in FEV1 was larger with each successive office
Economic impact of severe exacerbations
In addition to their clinical impact, severe exacerbations have major economic consequences. Hospital admissions are by far the largest source of medical expenditures for COPD in the United States, accounting for ≤70% of the total costs of medical care for this disease. Approximately 20% of patients with COPD account for nearly 80% of the total costs.18 In 2003, COPD accounted for >600,000 hospital admissions in the United States, with a mean length of stay of 5 days, a mean cost per
Prevention of chronic obstructive pulmonary disease exacerbations
Because COPD exacerbations and associated hospitalizations for COPD have significant human and economic consequences, their prevention should be a major goal of COPD management. A number of interventions for this purpose are either proved or are under continuing investigation, and these include pharmacologic therapies, immune modulation, and case management.
Both inhaled long-acting bronchodilators and inhaled corticosteroids reduce COPD exacerbation rates. The evidence supporting this
Summary
COPD exacerbations are serious medical events. They adversely affect QOL acutely and recovery occurs only slowly over a period of weeks or months. Not surprisingly, QOL deteriorates more rapidly in those patients with frequent exacerbations. Exacerbations may also be associated with a more rapid decline in lung function over time, thus accelerating the natural progression of the disease. Exacerbations have a huge economic impact. Patients with more severe exacerbations frequently seek medical
References (45)
- et al.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial
Lancet
(1999) - et al.
A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes
Clin Ther
(2002) - et al.
Quality of life in acute exacerbation of chronic bronchitis: results from a German population study
Respir Med
(2002) - et al.
Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases
Chest
(2002) - et al.
The costs of treating COPD in the United States
Chest
(2001) - et al.
Pharmacoeconomic evaluation of COPD
Chest
(2000) - et al.
The functional impact of adding salmeterol and tiotropium in patients with stable COPD
Respir Med
(2004) - et al.
Prophylactic use of influenza vaccine in patients with chronic bronchitis: a pilot trial
Lancet
(1961) - et al.
Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study
Chest
(2004) - et al.
Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(2005)
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
Ann Intern Med
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
N Engl J Med
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
Eur Respir J
Physiological changes during symptom recovery from moderate exacerbations of COPD
Eur Respir J
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Eur Respir J
Time course of recovery of health status following an infective exacerbation of chronic bronchitis
Thorax
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
BMJ
Impact of preventing exacerbations on deterioration of health status in COPD
Eur Respir J
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease
Thorax
Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study
Am J Respir Crit Care Med
Cited by (74)
Primary and secondary care clinicians' views on self-treatment of COPD exacerbations: A multinational qualitative study
2014, Patient Education and CounselingPrimary Care Provider Experience With Proactive E-Consults to Improve COPD Outcomes and Access to Specialty Care
2023, Chronic Obstructive Pulmonary DiseasesHealth System Approach to Improve Chronic Obstructive Pulmonary Disease Care after Hospital Discharge Stepped-Wedge Clinical Trial
2022, American Journal of Respiratory and Critical Care MedicinePatient-Centered Discussion on End-of-Life Care for Patients with Advanced COPD
2022, Medicina (Lithuania)